Pharmaceuticals firm Lupin Ltd on Wednesday said it has received an approval from the US health regulator for the generic version of Brivaracetam tablets used for control of partial onset seizures.
The approval by the US Food and Drug Administration (USFDA) is for Brivaracetam tablets of strengths 10 mg, 25 mg, 50 mg, 75 mg, and 100 mg, the company said in a regulatory filing.
These are the generic equivalent of Briviact tablets, 10 mg, 25 mg, 50 mg, 75 mg, and 100 mg, of UCB Inc, it added.
The product will be manufactured at Lupin's facility in Nagpur.
The Brivaracetam tablets had estimated annual sales of USD 420 million in the US, the company said citing IQVIA MAT September 2022 data.
Lupin Receives USFDA's Nod For Generic Version Of Brivaracetam Tablets
The approval by the US Food and Drug Administration (USFDA) is for Brivaracetam tablets of strengths 10 mg, 25 mg, 50 mg, 75 mg, and 100 mg
Lupin Receives USFDA's Nod For Generic Version Of Brivaracetam Tablets
Lupin Receives USFDA's Nod For Generic Version Of Brivaracetam Tablets
- Previous Story
Nearly 98% Rs 2000 Banknotes Returned; Rs 6,970 Crore Worth Notes Still with Public - Next StorySEBI Cautions Investors against Unauthorized Virtual Trading, Gaming Platforms
Just one email a week